Senti Biosciences, Inc. (SNTI)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Comprehensive loss | - | -28,866 | -11,203 | |
| Net loss from continuing operations | - | -28,866 | -11,203 | |
| Impairment of long-lived assets | - | 313 | - | |
| Research and development | 10,029 | 8,655 | 9,151 | |
| General and administrative | 6,769 | 6,247 | 4,205 | |
| Total operating expenses | 16,798 | 15,215 | 13,356 | |
| Loss from operations | -16,798 | -15,215 | -13,356 | |
| Genefab sublease income - related party | - | 1,657 | 1,587 | |
| Change in fair value | - | -15,447 | 324 | |
| Genefab sublease income - related party-Related Party | 1,586 | - | - | |
| Other income | 209 | -11 | 6 | |
| Interest income | 270 | 150 | 236 | |
| Change in fair value-Gene Fab Option | - | - | - | |
| Change in fair value-Gene Fab Note Receivable | - | - | - | |
| Change in fair value-Gene Fab Economic Share | - | - | - | |
| Total other income | 2,065 | -13,651 | 2,153 | |
| Net loss | -14,733 | -28,866 | -11,203 | |
| Net loss per share, basic (in dollars per share) | -0.56 | -6.31 | -2.45 | |
| Net loss per share, diluted (in dollars per share) | -0.56 | -6.31 | -2.45 | |
| Weighted-average number of shares used in computing net loss per share, basic (in shares) | 26,081,273 | 4,577,122 | 4,572,010 | |
| Weighted-average number of shares used in computing net loss per share, diluted (in shares) | 26,081,273 | 4,577,122 | 4,572,010 | |